Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Launched by M.D. ANDERSON CANCER CENTER · Aug 12, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how whole brain radiation therapy affects memory and thinking skills in patients with certain blood cancers, such as lymphoma, leukemia, and myeloma. The goal is to understand the impact of this treatment on neurocognitive outcomes, which means how well the brain functions after receiving radiation. By learning more about these effects, researchers hope to improve care for patients undergoing similar treatments in the future.

To participate in this study, individuals must be at least 18 years old and have received radiation therapy to the brain for a blood cancer. Participants should be able to complete tests in English, but those who experience claustrophobia can still join if it's managed with medication. If you decide to participate, you can expect to undergo assessments to evaluate how your thinking and memory may have changed after treatment. The trial is currently recruiting participants, and everyone is welcome regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma)
• • Proficient and capable of completing tests in English
• • Patients with claustrophobia are eligible if the claustrophobia is managed with medication
• • Patients with cognitively-impairment are eligible if the impairment is managed with medication
• • Patients who are pregnant